Share

March 24, 2020; 94 (12) Clinical/Scientific Notes

Drisapersen associated with elevated serum factor VIII levels in Duchenne muscular dystrophy

Hugh J. McMillan, Ali Amid, Hernan Gonorazky, Sulaiman Almobarak, Craig Campbell
First published February 19, 2020, DOI: https://doi.org/10.1212/WNL.0000000000009139
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
90

Share

Article Information

vol. 94 no. 12 538-540
DOI: 
https://doi.org/10.1212/WNL.0000000000009139
PubMed: 
32075891
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received November 12, 2019
  • Accepted in final form January 14, 2020
  • First Published February 19, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Hugh J. McMillan, MD, MSc,
    2. Ali Amid, MD,
    3. Hernan Gonorazky, MD,
    4. Sulaiman Almobarak, MD and
    5. Craig Campbell, MD, MSc
  1. Hugh J. McMillan, MD, MSc,
    2. Scientific Advisory Boards:

    1. (1) AveXis (2) Muscular Dystrophy Canada (non-profit entity)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Muscle Nerve, Editorial Board Member (2016-present); (2) Journal Child Neurology, Editorial Board Member (2011- present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Principal Investigator for clinical trials with Sarepta Therapeutics

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ali Amid, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel grants for scientific meetings by Novo Nordisk and Octa Pharma. Speaker honororia by Takeda.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Hernan Gonorazky, MD,
    4. Scientific Advisory Boards:

    1. (1) Serving on a scientific advisory board for Novartis and Biogen

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sulaiman Almobarak, MD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Craig Campbell, MD, MSc
    6. Scientific Advisory Boards:

    1. (1) Catabasis and Solid Therapeutics DSMB, (2) PTC Therapeutics, Roche and Biogen Scientific Advisory Board Chair (volunteer)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Valerion Pharmaceuticals (2)PTC Therapeutics (3) Biogen , (4) GEnzyme. Investigator initiated grants. (5) Site investigator for clinical trials: Acceleron, Biogen, Biomarin, AMO, Catabasis, Cytokinetics, GSK, Prosensa, Pfizer, PTC, Roche, Sarepta, Wave.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Child Health Foundation (2) Jesse's Journey Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Pediatrics (H.J.M., A.A.), Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa; Department of Pediatrics (H.G.), Sick Kids Hospital, University of Toronto, Toronto; and Department of Pediatrics (S.A., C.C.), London Children's Hospital, University of Western Ontario, London, Ontario, Canada.
  1. Correspondence
    Dr. McMillan hmcmillan{at}cheo.on.ca
View Full Text

Article usage

Article usage: February 2020 to February 2023

AbstractFullPdfSource
Feb 2020153020Highwire
Mar 20202543120Highwire
Apr 20201021612Highwire
May 202070916Highwire
Jun 20204301Highwire
Jul 20203510Highwire
Aug 20203521Highwire
Sep 20205711Highwire
Oct 20206212Highwire
Nov 20203640Highwire
Dec 20203000Highwire
Jan 20211601Highwire
Feb 20212502Highwire
Mar 20212112Highwire
Apr 20217404Highwire
May 20214321Highwire
Jun 20212730Highwire
Jul 20213200Highwire
Aug 20216100Highwire
Sep 20212401Highwire
Oct 20213210Highwire
Nov 20213910Highwire
Dec 20212300Highwire
Jan 20221700Highwire
Feb 20223400Highwire
Mar 20222901Highwire
Apr 20223500Highwire
May 20222100Highwire
Jun 20222700Highwire
Jul 20222211Highwire
Aug 20222710Highwire
Sep 20222500Highwire
Oct 20223821Highwire
Nov 20223603Highwire
Dec 20223300Highwire
Jan 20233600Highwire
Feb 20232700Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles